First performed in 1963, lung transplantation is approaching the half-century mark. With
more than 32,000 procedures having been performed worldwide, lung transplantation has …

Lung transplantation is a therapeutic option for patients with end-stage pulmonary disorders.
Unfortunately, due to post–lung transplant complications, both infectious and noninfectious …

Rationale: Long-term survival after lung transplantation is limited by infectious complications
and by bronchiolitis obliterans syndrome (BOS), a form of chronic rejection linked in part to …

Invasive aspergillosis (IA) occurs in 1–15% of the solid organ transplant (SOT) recipients.
Mortality rate in transplant recipients with IA historically has ranged from 65% to 92%(1, 2, 3 …

Lung transplantation has become an accepted therapeutic procedure for the treatment of
end‐stage pulmonary parenchymal and vascular disease. Despite improved survival rates …

Allograft infection after lung transplantation has a significant impact on the outcome and can
be a diagnostic challenge. The increased susceptibility of the pulmonary allograft to infection …

The aim of this study was to assess the outcome and tolerability of prophylactic nebulized
liposomal amphotericin B (n‐LAB) in lung transplant recipients (LTR) and the changing …

Immunosuppression remains the mainstay of therapy for successful outcomes after lung
transplantation. The need for optimal immunosuppression became evident to maintain long …

Rationale: Pseudomonas aeruginosa is the most commonly isolated gram-negative
bacterium after lung transplantation and has been shown to up-regulate glutamic acid …

Infections with cytomegalovirus (CMV) can induce severe complications after solid organ
transplantation (SOT). The prognosis for ganciclovir‐resistant CMV infection and disease is …